Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended September 30, 2004 (Fiscal Year 2005)
Business Overview: McKesson operates in three primary segments: Pharmaceutical Solutions (distribution of drugs and health products), Medical-Surgical Solutions (distribution of medical supplies), and Provider Technologies (healthcare software and automation). The company reorganized its reporting segments effective April 1, 2004.
Key Financial Metrics
| Metric (in millions) | Q2 2004 | Q2 2003 | 6 Months 2004 | 6 Months 2003 |
|---|---|---|---|---|
| Revenues | $19,934.3 | $16,810.1 | $39,120.9 | $33,334.3 |
| Gross Profit | $735.0 | $811.7 | $1,587.0 | $1,598.2 |
| Operating Income | $128.8 | $227.1 | $389.6 | $478.7 |
| Net Income | $86.1 | $156.5 | $249.7 | $312.1 |
| Diluted EPS | $0.29 | $0.53 | $0.84 | $1.05 |
| Cash from Operations (6mo) | $382.0 (2004) vs. $(298.3) (2003) | |||
| Total Assets | $17,965.7 (Sep 30, 2004) | |||
| Long-Term Debt | $1,205.1 (Sep 30, 2004) | |||
| Working Capital | $3,904.7 (Sep 30, 2004) |
Margins (Quarter Ended Sep 30, 2004):
- Gross Profit Margin: 3.69% (down 114 bps from prior year)
- Operating Margin: 0.65% (down significantly from prior year)
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 19% in the quarter and 17% year-to-date, driven primarily by the Pharmaceutical Solutions segment (94% of total revenue). Growth was fueled by market expansion, new customers (including a major Department of Veterans Affairs contract), and favorable foreign exchange rates in Canada.
- Profitability Decline: Net income dropped 45% in the quarter and 20% year-to-date. This was primarily due to a decline in volume-weighted price increases for U.S. pharmaceutical products, which reduced gross margins in the Pharmaceutical Solutions segment.
- Margin Compression: Consolidated gross profit margin decreased to 3.69% from 4.83% in the prior year quarter. The Pharmaceutical Solutions margin fell to 2.28% from 3.22% due to lower manufacturer price increases and competitive pricing pressures.
- Operating Expenses: Increased 4% in the quarter, largely due to costs associated with the acquisition of Moore Medical Corp. (MMC), litigation reserves, and pension settlement charges.
- Cash Flow Improvement: Operating cash flow turned positive ($382.0 million) compared to a negative $298.3 million in the prior year, attributed to improved receivables collections and inventory management.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Fee-for-Service Transition: Management is actively restructuring distribution agreements with manufacturers to shift from price-inflation-based compensation to fee-for-service models. They aim to substantially complete this process by the fiscal year-end (March 31, 2005).
- Acquisition Integration: The company anticipates completing an evaluation of its distribution center network following the MMC acquisition in the third quarter of 2005.
- NHS Contract: The company is negotiating with the UK's National Health Services (NHS) to amend terms of a $500 million contract. Delays have increased costs and reduced revenue recognition. Management believes recovery of the $86 million investment is likely but notes uncertainty regarding the outcome of negotiations.
Risks and Contingencies
- Legal Proceedings: Significant shareholder litigation regarding the 1999 financial restatement remains pending. A recent court award of $0.7 million in attorney fees is being appealed.
- Customer Bankruptcy: A $30.0 million provision for doubtful accounts was recorded in the prior year due to a customer bankruptcy; a $40.0 million guarantee was converted to a note receivable in the current period.
- Market Risks: Exposure to changes in manufacturer pricing policies, consolidation of competitors/customers, and foreign currency fluctuations.
Unusual Items
- Antitrust Settlement: A $41.2 million cash receipt from an antitrust class action settlement was recorded as a reduction in cost of sales in the first half of 2005.
- Tax Benefits: A $15.3 million tax benefit was recognized in Q2 2004 from favorable IRS settlements regarding prior years. A $6.4 million benefit was recognized in Q2 2005 from reduced valuation allowances on state net operating losses.
- Pension Settlements: Approximately $12 million in settlement charges were expensed in the first half of 2005 related to lump-sum payments from an unfunded pension plan.
Investor Verification Checklist
- Margin Sustainability: Verify the timeline and success of the transition to fee-for-service agreements with pharmaceutical manufacturers to stabilize gross margins.
- NHS Contract Resolution: Monitor the outcome of negotiations with the UK NHS regarding the $500 million contract and potential impairment of the $86 million invested assets.
- Legal Exposure: Track the status of the shareholder litigation regarding the 1999 restatement and the potential financial impact of the Charlene Roby judgment appeal.
- Working Capital Management: Assess the company's ability to manage the substantial working capital requirements of the Pharmaceutical Solutions segment amidst inventory purchase patterns.
- Debt Covenants: Confirm continued compliance with the debt-to-capital ratio covenant (currently 21.0%, limit 56.5%) to avoid acceleration of debt repayment.